GE HealthCare (GEHC) announced that it has received FDA premarket authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Strategic Acquisition of Intelerad Boosts GE Healthcare’s SaaS Offerings and Revenue Potential
- GE Healthcare’s Strategic Acquisition of Intelerad: Balancing Long-Term Gains with Short-Term Challenges
- Hold Rating on GE Healthcare Technologies Inc: Strategic Acquisition of Intelerad Brings Long-Term Growth Potential Amid Initial EPS Dilution Concerns
- GE Healthcare’s Intelerad Acquisition: Balancing Long-term Growth with Short-term EPS Dilution
- GE HealthCare to acquire Intelerad for $2.3B in cash